Arca BioPharma hopeful about personalized beta blocker

07/28/2008 | American City Business Journals

Arca BioPharma is inching closer to launching bucindolol, an experimental beta blocker that would be the first genetically targeted heart-failure drug. The biotech firm intends to file this week for FDA approval of the drug along with a genetic test being developed by partner Lab Corp.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC